Immune Modulatory Therapy with LDN and Peptides for Chronic Lyme, CIRS, CFS, ME, and Fibromyalgia

Chronic vector-borne illness is a rapidly growing epidemic around the world. Such infections often result in a multi-system illness that can result in numerous disease syndromes, misdiagnoses, and multiple secondary diagnoses. This lecture will describe how infection-induced TH1/Treg to TH2/Th17 immune shift can cause or contribute to all of the multi-system pathophysiology seen with chronic Lyme disease, chronic fatigue syndrome (CFS), fibromyalgia, CIRS, a wide variety of autoimmune diseases (MS, lupus, RA, Hashimoto’s, etc.), and neurodegenerative diseases (ALS, Alzheimer’s, Parkinson’s, etc.), as well as migraines, depression, anxiety, cognitive dysfunction, muscle and joint pain, insomnia, addiction, schizophrenia, diabetes, cardiovascular disease, mitochondrial dysfunction, weight gain, aging, hypercholesterolemia, and many more.

Immune modulatory therapies such as peptides and LDN that address the abnormal TH1/Treg-TH2/Th17 shift in immunity and subsequent vicious cycles of dysfunction is an essential strategy for successful long-term treatment of chronic Lyme disease and a key target for the treatment of a wide range of chronic illnesses and diseases of aging. Failure to address the immune dysfunction in chronic infectious diseases is a common cause of treatment failure.

Specific peptides can also be used to treat the particular aspects and symptoms seen with multi-system illnesses, including sleep disorders, cognitive dysfunction, mitochondrial dysfunction, hypercoagulation, gastrointestinal disorders, chronic pain, neurologic dysfunction, mast cell activation, hormone deficiencies, autoimmunity, excess oxidative stress, insulin resistance, weight gain, hypothalamic-pituitary dysfunction, thyroid resistance, depression and anxiety, and many more.